Based on the outcomes of the WHO/MPP mRNA regional R&D meeting, held 31 October-1 November 2023 in
Bangkok, Kingdome of Thailand, WHO and MPP are looking to establish the following research consortia to
advance mRNA vaccine development up to proof of concept:
- A consortium on dengue mRNA vaccine product development to be led by the International Vaccine Institute
(IVI), in collaboration with Chula VRC, Chulalongkorn University and mRNA manufacturing partners from
Bangladesh and Indonesia.
- A consortium on hand, foot and mouth disease (HFMD) mRNA product development to be led by Hilleman labs
in collaboration with Chula VRC, Chulalongkorn University, National University of Singapore and mRNA
manufacturing partners from Vietnam.
- A consortium on therapeutic human papillomavirus (HPV) mRNA product development to be led initially by
Chula VRC, Chulalongkorn University.
- A consortium on plasmodium vivax malaria mRNA product development to be led by Mahidol University in
collaboration with Chula VRC, Chulalongkorn University.
Objectives of the meeting
The proposed objectives are to:
1) Review key scientific and technical considerations for mRNA vaccine development against dengue,
HFMD, P. vivax and therapeutic HPV.
2) Discuss key roles and responsibilities of partners engaged in proposed consortia to advance mRNA
vaccine development up to proof of concept early phase clinical development.
3) For each of the disease, discuss terms of MoU that will form the basis of the R&D consortia.
4) Discuss investment opportunities to support regional R&D collaboration.
Meeting material
Presentations
Day 1
Day 2